1-20 of 24
Jann N. Sarkaria
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits

Open Access
Sonja Dragojevic, Emily J. Smith, Michael S. Regan, Sylwia A. Stopka, Gerard Baquer, Zhiyi Xue, Wenjuan Zhang, Margaret A. Connors, Jake A. Kloeber, Zeng Hu, Katrina K. Bakken, Lauren L. Ott, Brett L. Carlson, Danielle M. Burgenske, Paul A. Decker, Shulan Tian, Shiv K. Gupta, Daniel J. Laverty, Jeanette E. Eckel-Passow, William F. Elmquist, Nathalie Y.R. Agar, Zachary D. Nagel, Jann N. Sarkaria, Cameron M. Callaghan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2025) 24 (6): 859–869.
https://doi.org/10.1158/1535-7163.MCT-24-0003
Published: 04 June 2025
View article titled, DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits
Open the PDF for DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits in another window
Includes: Supplementary data
Journal Articles

Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628

Open Access
Darwin A. Garcia, Sneha Rathi, Margaret A. Connors, Michael Grams, Rachael A. Vaubel, Katrina K. Bakken, Lauren L. Ott, Brett L. Carlson, Zeng Hu, Paul A. Decker, Jeanette E. Eckel-Passow, Danielle M. Burgenske, Wei Zhong, Joshua D. Trzasko, Michael G. Herman, William F. Elmquist, Nicholas B. Remmes, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2025) 24 (2): 299–309.
https://doi.org/10.1158/1535-7163.MCT-24-0664
Published: 04 February 2025
View article titled, Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628
Open the PDF for Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628 in another window
Includes: Supplementary data
Journal Articles

Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

Open Access
Jianxiong Ji, Sonja Dragojevic, Cameron M. Callaghan, Emily J. Smith, Surabhi Talele, Wenjuan Zhang, Margaret A. Connors, Ann C. Mladek, Zeng Hu, Katrina K. Bakken, Paige P. Sarkaria, Brett L. Carlson, Danielle M. Burgenske, Paul A. Decker, Mohammad Abdur Rashid, Mi-hyeon Jang, Shiv K. Gupta, Jeanette E. Eckel-Passow, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (5): 662–671.
https://doi.org/10.1158/1535-7163.MCT-23-0552
Published: 02 May 2024
View article titled, Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts
Open the PDF for Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts in another window
Includes: Supplementary data
Journal Articles

Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma

Available to Purchase
Wenjuan Zhang, Rachael A. Vaubel, Ju-Hee Oh, Ann C. Mladek, Surabhi Talele, Wenqiu Zhang, Katie L. Waller, Danielle M. Burgenske, Jann N. Sarkaria, William F. Elmquist
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 47–55.
https://doi.org/10.1158/1535-7163.MCT-23-0217
Published: 03 January 2024
View article titled, Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma
Open the PDF for Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract A148: The radiosensitizing effects of the novel brain penetrant and potent ATM inhibitor WSD0628 in glioblastoma and melanoma patient derived xenografts

Free
Zhiyi Xue, Ann C. Mladek, Sneha Rathi, Danielle M. Burgenske, Shiv K. Gupta, Brett L. Carlson, Zeng Hu, Lauren L Ott, Katrina K. Bakken, Rachael A. Vaubel, William F Elmquist, Wei Zhong, Jann N Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A148.
https://doi.org/10.1158/1535-7163.TARG-23-A148
Published: 01 December 2023
View article titled, Abstract A148: The radiosensitizing effects of the novel brain penetrant and potent ATM inhibitor WSD0628 in glioblastoma and melanoma patient derived xenografts
Journal Articles

Abstract A002: The utility of pre-clinical trials in glioblastoma patient-derived xenografts (PDXs) models for informing clinical trial development of therapeutic strategies

Free
Danielle M Burgenske, Ann C Mladek, Katrina K Bakken, Zeng Hu, Brett L Carlson, Paul A Decker, Jeanette E Eckel-Passow, Jann N Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A002.
https://doi.org/10.1158/1535-7163.TARG-23-A002
Published: 01 December 2023
View article titled, Abstract A002: The utility of pre-clinical trials in glioblastoma patient-derived xenografts (PDXs) models for informing clinical trial development of therapeutic strategies
Journal Articles

In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

Available to Purchase
Sani H. Kizilbash, Shiv K. Gupta, Karen E. Parrish, Janice K. Laramy, Minjee Kim, Gautham Gampa, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (6): 1009–1018.
https://doi.org/10.1158/1535-7163.MCT-20-0640
Published: 01 June 2021
View article titled, In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
Open the PDF for In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling in another window
Includes: Supplementary data
Journal Articles

Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy

Available to Purchase
Christian K. Werner, Uchechi J. Nna, Hanshi Sun, Kari Wilder-Romans, Joseph Dresser, Ayesha U. Kothari, Weihua Zhou, Yangyang Yao, Arvind Rao, Stefanie Stallard, Carl Koschmann, Tarik Bor, Waldemar Debinski, Alexander M. Hegedus, Meredith A. Morgan, Sriram Venneti, Edwina Baskin-Bey, Daniel E. Spratt, Howard Colman, Jann N. Sarkaria, Arul M. Chinnaiyan, Joel R. Eisner, Corey Speers, Theodore S. Lawrence, Roy E. Strowd, Daniel R. Wahl
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (10): 2163–2174.
https://doi.org/10.1158/1535-7163.MCT-20-0095
Published: 02 October 2020
View article titled, Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy
Open the PDF for Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy in another window
Includes: Supplementary data
Journal Articles

ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Free
Xinyi Tu, Mohamed M. Kahila, Qin Zhou, Jia Yu, Krishna R. Kalari, Liewei Wang, William S. Harmsen, Jian Yuan, Judy C. Boughey, Matthew P. Goetz, Jann N. Sarkaria, Zhenkun Lou, Robert W. Mutter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (11): 2462–2472.
https://doi.org/10.1158/1535-7163.MCT-18-0470
Published: 02 November 2018
View article titled, ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Open the PDF for ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Free
Minjee Kim, Daniel J. Ma, David Calligaris, Shuangling Zhang, Ryan W. Feathers, Rachael A. Vaubel, Isabelle Meaux, Ann C. Mladek, Karen E. Parrish, Fang Jin, Cedric Barriere, Laurent Debussche, James Watters, Shulan Tian, Paul A Decker, Jeanette E. Eckel-Passow, Gaspar J. Kitange, Aaron J. Johnson, Ian F. Parney, Panos Z. Anastasiadis, Nathalie Y.R. Agar, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (9): 1893–1901.
https://doi.org/10.1158/1535-7163.MCT-17-0600
Published: 04 September 2018
View article titled, Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Open the PDF for Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier in another window
Includes: Supplementary data
Journal Articles

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

Free
Sani H. Kizilbash, Shiv K. Gupta, Kenneth Chang, Ryo Kawashima, Karen E. Parrish, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, Gaspar J. Kitange, Yuqiao Shen, Ying Feng, Andrew A. Protter, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (12): 2735–2746.
https://doi.org/10.1158/1535-7163.MCT-17-0365
Published: 03 December 2017
View article titled, Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Open the PDF for Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma

Free
Rebecca S. Lescarbeau, Liang Lei, Katrina K. Bakken, Peter A. Sims, Jann N. Sarkaria, Peter Canoll, Forest M. White
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (6): 1332–1343.
https://doi.org/10.1158/1535-7163.MCT-15-0692
Published: 02 June 2016
View article titled, Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma
Open the PDF for Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Free
Karen E. Parrish, Ling Cen, James Murray, David Calligaris, Sani Kizilbash, Rajendar K. Mittapalli, Brett L. Carlson, Mark A. Schroeder, Julieann Sludden, Alan V. Boddy, Nathalie Y.R. Agar, Nicola J. Curtin, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12): 2735–2743.
https://doi.org/10.1158/1535-7163.MCT-15-0553
Published: 06 December 2015
View article titled, Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
Open the PDF for Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System in another window
Includes: Supplementary data
Journal Articles

NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification

Free
Yasuyuki Yoshida, Tomoko Ozawa, Tsun-Wen Yao, Wang Shen, Dennis Brown, Andrew T. Parsa, Jeffrey J. Raizer, Shi-Yuan Cheng, Alexander H. Stegh, Andrew P. Mazar, Francis J. Giles, Jann N. Sarkaria, Nicholas Butowski, Theodore Nicolaides, C. David James
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (12): 2919–2929.
https://doi.org/10.1158/1535-7163.MCT-14-0306
Published: 04 December 2014
View article titled, NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification
Open the PDF for NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification in another window
Includes: Supplementary data
Journal Articles

Abstract B37: Proteomic and metabolomic analyses of glioblastoma using mass spectrometry.

Free
Soo Jung Ha, Gordon Showalter, Jenna Rickus, Shanbao Cai, Haiyan Wang, Wei Michael Liu, Jann N. Sarkaria, John Springer, Jiri Adamec, Karen E. Pollok, Kari L. Clase
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B37.
https://doi.org/10.1158/1535-7163.TARG-13-B37
Published: 01 November 2013
View article titled, Abstract B37: Proteomic and metabolomic analyses of glioblastoma using mass spectrometry.
Journal Articles

Abstract C81: BBB efflux pump activity limits brain penetration of palbociclib (PD0332991) in glioblastoma.

Free
Karen E. Parrish, Jenny L. Pokorny, Rajendar K. Mittapalli, Katrina Bakken, Jann N. Sarkaria, William F. Elmquist
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C81.
https://doi.org/10.1158/1535-7163.TARG-13-C81
Published: 01 November 2013
View article titled, Abstract C81: BBB efflux pump activity limits brain penetration of palbociclib (PD0332991) in glioblastoma.
Journal Articles

Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents

Free
Sagar Agarwal, Rajendar K. Mittapalli, David M. Zellmer, Jose L. Gallardo, Randy Donelson, Charlie Seiler, Stacy A. Decker, Karen S. SantaCruz, Jenny L. Pokorny, Jann N. Sarkaria, William F. Elmquist, John R. Ohlfest
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (10): 2183–2192.
https://doi.org/10.1158/1535-7163.MCT-12-0552
Published: 09 October 2012
View article titled, Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents
Open the PDF for Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents in another window
Includes: Supplementary data
Journal Articles

Abstract B100: Preclinical evaluation of a novel HSP90 inhibitor HSP990 in glioblastoma multiforme.

Free
Meena Shrivastav, Jamie L. Ostrem, Guido C. Gonzales, Ian F. Parney, Brett L. Carlson, Mark A. Schroeder, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B100.
https://doi.org/10.1158/1535-7163.TARG-11-B100
Published: 12 November 2011
View article titled, Abstract B100: Preclinical evaluation of a novel HSP90 inhibitor HSP990 in glioblastoma multiforme.
Journal Articles

Abstract B68: Differential gene expression associated with temozolomide resistance development in glioblastoma xenografts.

Free
Ryan S. Youland, Gaspar J. Kitange, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B68.
https://doi.org/10.1158/1535-7163.TARG-11-B68
Published: 12 November 2011
View article titled, Abstract B68: Differential gene expression associated with temozolomide resistance development in glioblastoma xenografts.
Journal Articles

ZD6474, a Multitargeted Inhibitor for Receptor Tyrosine Kinases, Suppresses Growth of Gliomas Expressing an Epidermal Growth Factor Receptor Mutant, EGFRvIII, in the Brain

Free
Jia-Jean Yiin, Bo Hu, Paul A. Schornack, Raghvendra S. Sengar, Kun-wei Liu, Haizhong Feng, Frank S. Lieberman, Shih-Hwa Chiou, Jann N. Sarkaria, Erik C. Wiener, Hsin-I Ma, Shi-Yuan Cheng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (4): 929–941.
https://doi.org/10.1158/1535-7163.MCT-09-0953
Published: 07 April 2010
View article titled, ZD6474, a Multitargeted Inhibitor for Receptor Tyrosine Kinases, Suppresses Growth of Gliomas Expressing an Epidermal Growth Factor Receptor Mutant, EGFRvIII, in the Brain
Open the PDF for ZD6474, a Multitargeted Inhibitor for Receptor Tyrosine Kinases, Suppresses Growth of Gliomas Expressing an Epidermal Growth Factor Receptor Mutant, EGFRvIII, in the Brain in another window
Includes: Supplementary data